PL EN
Chlorochine Retinopathy in COVID-19 Pandemic
 
 
More details
Hide details
1
Centrum Mikrochirurgii Oka LASER w Warszawie
 
 
Publication date: 2023-12-30
 
 
Ophthalmology 2022;(3):32-42
 
KEYWORDS
ABSTRACT
Hydroxychloroquine (HCQ, Plaquenil) is used in treatment of a variety of autoimmune disorders, in dermatology, rheumatology and oncology. Hydroxychloroquine and chloroquine (CQ) have been associated with irreversible visual loss due to retinal toxicity. Hydroxychloroquine retinal toxicity is far more common than previously considered; an overall prevalence of 7.5% was identified in patients taking HCQ for greater than 5 years, rising to almost 20% after 20 years of treatment. SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is causing the COVID-19 pandemic. There is no current standard of care. Clinicians need to be mindful of the toxicity of a wide variety of possibly unfamiliar substances being tested or repurposed to treat COVID-19.
eISSN:1689-362X
ISSN:1505-2753
Journals System - logo
Scroll to top